65 research outputs found

    Famille et filiation dans le théùtre expérimental de Noëlle Renaude

    Get PDF
    Les oeuvres thĂ©Ăątrales de NoĂ«lle Renaude (nĂ©e Ă  Paris en 1949) s’insĂšrent dans le courant contemporain que les critiques ont baptisĂ© « le thĂ©Ăątre de voix ». Dans ce thĂ©Ăątre d’avant-garde, la parole dramatique peut se passer de situations, de personnages bien dĂ©finis et de didascalies. La parole n’est plus l’instrument de l’action : elle est l’action. Chaque Ă©nonciation engendre ses propres temps et espace. Comment susciter et retenir l’intĂ©rĂȘt des lecteurs lorsqu’on Ă©crit un texte thĂ©Ăątral sans situations ni fable ? Comment assurer la lisibilitĂ© de textes aussi fragmentĂ©s ? Dans les piĂšces de NoĂ«lle Renaude, on constate la rĂ©currence de quelques motifs — notamment la famille et la filiation — qui servent Ă  compenser l’éclatement radical de la forme dramatique, en crĂ©ant une apparence de profondeur psychologique ainsi que l’illusion d’une dimension spatio-temporelle.The plays of NoĂ«lle Renaude (born in Paris in 1949) fall within the contemporary wave that critics have christened “voice theatre.” In this avant-garde theatre, dramatic speech can do without situations, well-defined characters and stage direction. Speech is no longer the instrument of action: it is the action. Each pronouncement generates its own time and space. How does one arouse and retain the interest of readers when writing a play with neither situations nor a story? How can the legibility of such fragmented texts be ensured? In the plays of NoĂ«lle Renaude, one observes the reoccurrence of a few motifs—notably the family and relationship—which serve to compensate for the radical breakdown of dramatic form by creating an appearance of psychological depth as well as the illusion of a spatio-temporal dimension

    Roman policier / roman exotique : René Leys de Victor Segalen

    Get PDF

    Perceptions of a mobile health intervention for Community Case Management in Malawi: Opportunities and challenges for Health Surveillance Assistants in a community setting

    Get PDF
    AbstractBackground Improved availability of mobile phones in low- and middle-income countries (LMICs) offer an opportunity to improve delivery of Community Case Management (CCM). Despite enthusiasm for introducing mHealth into healthcare across LMICs, end-user attitudes towards mHealth solutions for CCM are limited. We aimed to explore Health Surveillance Assistants’ (HSAs) perceptions of the Supporting LIFE electronic CCM Application (SL eCCM App) and their experiences incorporating it as part of their clinical practice. Methods This exploratory qualitative study was part of a mixed methods feasibility study investigating whether children under-5 presenting to village clinics could be followed-up to collect patient outcome data. The convenience sample of 12 HSAs enrolled into the feasibility study participated in semi-structured interviews, which were conducted at village clinics after HSAs had field-tested the SL eCCM App over a 10-day period. Interviews explored HSAs perceptions of the SL eCCM App and their experiences in using the App in addition to paper CCM to assess and treat acutely unwell children. Open coding was used to label emerging concepts, which were iteratively defined and developed into six key themes. Results HSAs’ perceived enhanced clinical decision-making, quality of CCM delivery, and work efficiency as opportunities associated with using the SL eCCM App. HSAs believed the inability to retrieve patient records,, cumbersome duplicate assessments/data entry study procedures, and inconsistencies between the SL eCCM App and paper-based CCM guidelines as challenges to implementation. Adding features to the App, such as, permitting communication between colleagues/supervisors, drug stock-out reporting, and community assessments, were identified as potentially supporting HSAs’ many roles in the community. Conclusion This study identified opportunities and challenges associated with using the SL eCCM App in Malawi. This information can be used to inform future development and evaluation of the SL eCCM App, and similar mHealth solutions for CCM in Malawi and other developing countries.

    The Fourteenth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the extended Baryon Oscillation Spectroscopic Survey and from the second phase of the Apache Point Observatory Galactic Evolution Experiment

    Get PDF
    The fourth generation of the Sloan Digital Sky Survey (SDSS-IV) has been in operation since July 2014. This paper describes the second data release from this phase, and the fourteenth from SDSS overall (making this, Data Release Fourteen or DR14). This release makes public data taken by SDSS-IV in its first two years of operation (July 2014-2016). Like all previous SDSS releases, DR14 is cumulative, including the most recent reductions and calibrations of all data taken by SDSS since the first phase began operations in 2000. New in DR14 is the first public release of data from the extended Baryon Oscillation Spectroscopic Survey (eBOSS); the first data from the second phase of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE-2), including stellar parameter estimates from an innovative data driven machine learning algorithm known as "The Cannon"; and almost twice as many data cubes from the Mapping Nearby Galaxies at APO (MaNGA) survey as were in the previous release (N = 2812 in total). This paper describes the location and format of the publicly available data from SDSS-IV surveys. We provide references to the important technical papers describing how these data have been taken (both targeting and observation details) and processed for scientific use. The SDSS website (www.sdss.org) has been updated for this release, and provides links to data downloads, as well as tutorials and examples of data use. SDSS-IV is planning to continue to collect astronomical data until 2020, and will be followed by SDSS-V.Comment: SDSS-IV collaboration alphabetical author data release paper. DR14 happened on 31st July 2017. 19 pages, 5 figures. Accepted by ApJS on 28th Nov 2017 (this is the "post-print" and "post-proofs" version; minor corrections only from v1, and most of errors found in proofs corrected

    Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.

    Get PDF
    UNLABELLED: Current treatment approaches for renal cell carcinoma (RCC) face challenges in achieving durable tumor responses due to tumor heterogeneity and drug resistance. Combination therapies that leverage tumor molecular profiles could offer an avenue for enhancing treatment efficacy and addressing the limitations of current therapies. To identify effective strategies for treating RCC, we selected ten drugs guided by tumor biology to test in six RCC patient-derived xenograft (PDX) models. The multitargeted tyrosine kinase inhibitor (TKI) cabozantinib and mTORC1/2 inhibitor sapanisertib emerged as the most effective drugs, particularly when combined. The combination demonstrated favorable tolerability and inhibited tumor growth or induced tumor regression in all models, including two from patients who experienced treatment failure with FDA-approved TKI and immunotherapy combinations. In cabozantinib-treated samples, imaging analysis revealed a significant reduction in vascular density, and single-nucleus RNA sequencing (snRNA-seq) analysis indicated a decreased proportion of endothelial cells in the tumors. SnRNA-seq data further identified a tumor subpopulation enriched with cell-cycle activity that exhibited heightened sensitivity to the cabozantinib and sapanisertib combination. Conversely, activation of the epithelial-mesenchymal transition pathway, detected at the protein level, was associated with drug resistance in residual tumors following combination treatment. The combination effectively restrained ERK phosphorylation and reduced expression of ERK downstream transcription factors and their target genes implicated in cell-cycle control and apoptosis. This study highlights the potential of the cabozantinib plus sapanisertib combination as a promising treatment approach for patients with RCC, particularly those whose tumors progressed on immune checkpoint inhibitors and other TKIs. SIGNIFICANCE: The molecular-guided therapeutic strategy of combining cabozantinib and sapanisertib restrains ERK activity to effectively suppress growth of renal cell carcinomas, including those unresponsive to immune checkpoint inhibitors

    On the use of nanocellulose as reinforcement in polymer matrix composites

    Get PDF
    AbstractNanocellulose is often being regarded as the next generation renewable reinforcement for the production of high performance biocomposites. This feature article reviews the various nanocellulose reinforced polymer composites reported in literature and discusses the potential of nanocellulose as reinforcement for the production of renewable high performance polymer nanocomposites. The theoretical and experimentally determined tensile properties of nanocellulose are also reviewed. In addition to this, the reinforcing ability of BC and NFC is juxtaposed. In order to analyse the various cellulose-reinforced polymer nanocomposites reported in literature, Cox–Krenchel and rule-of-mixture models have been used to elucidate the potential of nanocellulose in composite applications. There may be potential for improvement since the tensile modulus and strength of most cellulose nanocomposites reported in literature scale linearly with the tensile modulus and strength of the cellulose nanopaper structures. Better dispersion of individual cellulose nanofibres in the polymer matrix may improve composite properties
    • 

    corecore